Speaker illustration

Doctor Ewelina Kulikowski

Resverlogix Corp., Calgary (Canada)

Apabetalone, a BET inhibitor, attenuates inflammation induced by viral RNA mimetic and reduces SARS-CoV-2 spike protein binding regardless of variants

Event: ESC Congress 2022

Topic: Pharmacotherapy

Session: Pericardial disease, myocardial disease, COVID-19


Apabetalone (RVX-208) inhibits key drivers of vascular inflammation, calcification, and plaque vulnerability through a BET-dependent epigenetic mechanism

Event: ESC Congress 2019

Topic: Inflammation and Immunity

Session: Coronary artery disease inflammation


Apabetalone (RVX-208) Reduces Monocyte-Endothelial Cell Adhesion and Expression of Key Vascular Inflammation Markers in Monocytes, Endothelial Cells and in Inflamed Mouse Aorta

Event: ESC Congress 2018

Topic: Genetics, Epigenetics, ncRNA

Session: Late Breaking Basic and Translational Science - Vascular Biology


Apabetalone (RVX-208) impacts key biomarkers and pathways associated with cardiovascular disease in patients with severe renal impairment

Event: ESC Congress 2017

Topic: CAD and comorbidities

Session: CAD and comorbidities


Modulation of the complement cascade in cardiovascular disease patients by a bromodomain and extraterminal (BET) protein inhibitor

Event: ESC Congress 2016

Topic: Inflammation and microcirculation

Session: Inflammation and immunity


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb